Evidence map›Paper›PMID 22821765›Full record

ArticleBlood2012

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Simona Blotta, Jana Jakubikova, Teresa Calimeri, Aldo M Roccaro, Nicola Amodio, Abdel Kareem Azab, Umberto Foresta, Constantine S Mitsiades, Marco Rossi, Katia Todoerti and 7 more

Abstract read
In one paragraph

Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. The role of KPNA3 in multiple myeloma: implications for targeting nuclear import.Apoptosis : an international journal on programmed cell death · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Current Status of Hedgehog Signaling Inhibitors.Current topics in medicinal chemistry · 2024
    Review
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Simona BlottaDana-Farber Cancer Institute, Boston, MA 02115, USA.
Jana Jakubikova
Teresa Calimeri
Aldo M Roccaro
Nicola Amodio
Abdel Kareem Azab
Umberto Foresta
Constantine S Mitsiades
Marco Rossi
Katia Todoerti
Stefano Molica
Fortunato Morabito
Antonino Neri
Piersandro Tagliaferri
Pierfrancesco Tassone
Kenneth C Anderson
Nikhil C Munshi
Dana-Farber Cancer Institute · USMagna Graecia University · ITVA Boston Healthcare System · USUniversity of Milan · ITAzienda Ospedaliera di Cosenza · ITAzienda Ospedaliera Pugliese Ciaccio · IT

Funding

Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0M
Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
Targeting Myeloma Cell-Host Bone Marrow InteractionsP01CA078378 · NCI · DANA-FARBER CANCER INSTITUTE · PI WELLER, EDIE A · 1998 to 2014
$26.2M
Role of Cytokines in Myeloma PathogenesisR01CA050947 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MITSIADES, CONSTANTINE S. · 1991 to 2018
$5.1M
A Universal Brain Atlas for Implanting and Managing Deep Brain StimulatorsR42MH100007 · NIMH · NEUROTARGETING, LLC · PI DHAESE, PIERRE F., KONRAD, PETER E · 2012 to 2014
$2.7M
CRF-Norepinephrine Interactions in Stress and DepressionR01MH050947 · NIMH · UNIVERSITY OF HAWAII AT MANOA · PI DUNN, ADRIAN JOHN · 1995 to 2008
$1.4M
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–
BLRD VA I01 BX001584NCI NIH HHS P01 CA078378NCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707NCI NIH HHS P50CA-100707NCI NIH HHS R01 CA050947NIMH NIH HHS P01-MH155258NIMH NIH HHS P01-MH78378NIMH NIH HHS P50-MH100007NIMH NIH HHS R01-MH124929NIMH NIH HHS R01-MH50947
6 · The paper itself

Abstract

The Hedgehog (Hh) pathway is required for cell-fate determination during the embryonic life, as well as cell growth and differentiation in the adult organism, where the inappropriate activation has been implicated in several cancers. Here we demonstrate that Hh signaling plays a significant role in growth and survival of multiple myeloma (MM) cells. We observed that CD138(+) MM cells express Hh genes and confirmed Smoothened (Smo)-dependent Hh signaling in MM using a novel synthetic Smo inhibitor, NVP-LDE225 (Novartis), which decreased MM cell viability by inducing specific down-regulation of Gli1 and Ptch1, hallmarks of Hh activity. In addition, we detected a nuclear localization of Gli1 in MM cells, which is completely abrogated by Forskolin, a Gli1-modulating compound, confirming Smo-independent mechanisms leading to Hh activation in MM. Finally, we identified that bone marrow stromal cells are a source of the Shh ligand, although they are resistant to the Hh inhibitor because of defective Smo expression and Ptch1 up-regulation. Further in vitro as well as in vivo studies showed antitumor efficacy of NVP-LDE225 in combination with bortezomib. Altogether, our data demonstrate activation of both canonical and noncanonical Hh pathway in MM, thus providing the rationale for testing Hh inhibitors in clinical trials to improve MM patient outcome.

Indexed as

Signal TransductionAnimalsAntineoplastic AgentsBiphenyl CompoundsBoronic AcidsBortezomibCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticHedgehog ProteinsHumansMiceMice, SCIDMultiple MyelomaPatched-1 ReceptorPatched ReceptorsAntineoplastic AgentsBiphenyl CompoundsBoronic AcidsBortezomibHedgehog ProteinsPatched-1 ReceptorPatched ReceptorsPTCH1 protein, humanPtch1 protein, mousePyrazinesPyridinesReceptors, Cell SurfaceReceptors, G-Protein-CoupledSmoothened ReceptorSMO protein, humansonidegibSyndecan-1

Identifiers

PMID22821765
PMCPMC3525024
OpenAlexW2033352055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.